OREX Financial Facts
Loss from operations: 42.53MCollaborative agreement: 895K
See Full Income Statement
Cash and cash equivalents: 74.43M
Total liabilities and stockholders' equity: 355.81M
See Full Balance Sheet
Orexigen Therapeutics (OREX) Earnings
|
Expand Research on OREX
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | +31.4% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -22.2% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3/12/14 | Q413 | -$0.21 | -$0.19 | -$0.02 | $857M | $900M | N/A |  | | Details | |
2/25/15  |
 |
Q414 | $0.00 | $0.21 | -$0.21 | $22.95M | $49.65M | N/A | | | Details |
| 11/13/17 | |
Q317 | -$1.35 | -$2.13 | +$0.78 | $18.9M | $24.2M | = | | | Details |
| 5/9/17 | |
Q117 | -$4.67 | N/A | N/A | $19.1M | $20M | = | | | Details |
| 8/8/17 | |
Q217 | -$2.00 | N/A | N/A | $23.4M | $19.14M | = | | | Details |
| 2/26/16 |
|
Q415 | -$0.12 | -$0.08 | -$0.04 | $4.9M | $14.07M | N/A | | | Details |
| 3/28/17 |
|
Q416 | -$1.69 | -$1.18 | -$0.51 | $13.88M | $13.95M | N/A | | | Details |
| 11/5/15 |
|
Q315 | -$0.09 | -$0.16 | +$0.07 | $10M | $12.17M | N/A | | | Details |
